+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID06749730

Study of Adebrelimab Combined with Apatinib and Gemcitabine-Cisplatin as First Treatment for Unresectable Advanced Biliary Tract Cancer

Led by Henan Cancer Hospital · Updated on 2024-12-27

63

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of anti-angiogenic drugs with PD-L1 gemcitabine and cisplatin to improve treatment options for patients with advanced unresectable biliary tract carcinoma BTC. This phase 2 study aims to assess the first-line treatment for BTC, focusing on enhancing the effectiveness of current therapies and providing more choices in China. The study involves treating participants with a combination of adebrelimab 1200 mg every three weeks, apatinib 250 mg daily, and a chemotherapy regimen of gemcitabine 1000 mgm2 and cisplatin 25 mgm2 administered on days 1 and 8 every three weeks. This single-arm study evaluates the combined effects of these drugs as a first-line therapy for unresectable BTC. Participants will be monitored for progression-free survival from the first dose until disease progression or death, with follow-up up to about six months after enrollment. Other outcomes include overall survival, objective response rate, duration of response, and incidence of treatment-related adverse events. Safety assessments will continue for 90 days after the last dose. The study duration and procedures are designed to carefully evaluate treatment effects and safety in patients aged 18 to 80 years with unresectable BTC.

CONDITIONS

Brief Title

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Research Team

Y

Ying Liu, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here